MPM Oncology Impact Management »

Maze Therapeatics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Maze Therapeatics (MAZE) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Maze Therapeatics

Tip: Access up to 7 years of quarterly data

All positions including Maze Therapeatics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Maze Therapeatics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $3.4M 81k 41.43

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Maze Therapeatics

Frazier Life Sciences Management
Trv Gp Iv
Deep Track Capital
Arch Venture Corp
BlackRock
AH Capital Management
Vanguard Group
VR Adviser
Alphabet
General Catalyst Group Management
Woodline Partners
TRV GP V
Logos Global Management
Bellevue Group
Marshall Wace

View all funds holding Maze Therapeatics